OCRELIZUMAB (OCREVUS) prior authorization at Molina Healthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Molina Healthcare reviews OCRELIZUMAB (OCREVUS) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody [EPC]. The FDA-approved indication (2017) is INJECTABLE. Molina Healthcare-specific context: Primary Medicaid MCO + ACA Marketplace in 21 states. 42 CFR Part 438 Subpart F applies. State Fair Hearing is the escalation path after internal MCO appeal.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Molina Healthcare's medical policy URL referenced in the cover letter
Molina Healthcare's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Medicaid MCO carve-outs
- Step therapy
- Specialty pharmacy denials
If the PA is denied
Molina Healthcare gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.molinahealthcare.com/providers) with the same packet plus a peer-reviewed citation supporting OCRELIZUMAB (OCREVUS)for the patient's indication.
Medicare Advantage path: if Molina Healthcare misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Contact Molina Healthcare
- Provider portal: https://www.molinahealthcare.com/providers
Frequently asked questions
What documentation does Molina Healthcare need for OCRELIZUMAB (OCREVUS) prior auth?
Molina Healthcare's typical PA packet for OCRELIZUMAB (OCREVUS): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Molina Healthcare?
Standard OCRELIZUMAB (OCREVUS) PA decisions at Molina Healthcare: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Molina Healthcare most often reject OCRELIZUMAB (OCREVUS) for?
Across Molina Healthcare's book the common rejection patterns include: Medicaid MCO carve-outs; Step therapy; Specialty pharmacy denials. For OCRELIZUMAB (OCREVUS) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Molina Healthcare on OCRELIZUMAB (OCREVUS)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the OCRELIZUMAB (OCREVUS) PA packet
Open ApprovalHelp — generate a OCRELIZUMAB (OCREVUS) prior-auth packet tailored to Molina Healthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com